Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Galera Therapeutics ( (GRTX) ) is now available.
On February 12, 2026, Galera Therapeutics, Inc. filed a Certificate of Amendment with the Delaware Secretary of State to modify the terms of its Series B Non-Voting Convertible Preferred Stock. The amendment permits the company’s board of directors, at its sole discretion, to convert some or all outstanding shares of this preferred stock into common stock based on the existing conversion ratio, following approval by the board and unanimous consent of Series B holders.
This governance change gives Galera greater flexibility to manage its equity capital structure and potentially streamline its share classes over time. By securing unanimous written consent from Series B preferred shareholders, the company has reduced the risk of stakeholder conflict around conversions while positioning itself to act quickly if strategic, financing, or market conditions make such conversions advantageous.
The most recent analyst rating on (GRTX) stock is a Hold with a $0.02 price target. To see the full list of analyst forecasts on Galera Therapeutics stock, see the GRTX Stock Forecast page.
Spark’s Take on GRTX Stock
According to Spark, TipRanks’ AI Analyst, GRTX is a Neutral.
The score is primarily held down by fragile financial fundamentals—no revenue, continuing losses, negative free cash flow, and especially the stressed balance sheet with negative equity and a large debt increase. Technical signals are also weak (negative MACD and sub-50 RSI), while valuation is constrained by unprofitability and lack of dividend support.
To see Spark’s full report on GRTX stock, click here.
More about Galera Therapeutics
Galera Therapeutics, Inc. is a biotechnology company focused on developing therapeutic products, operating within the life sciences and pharmaceutical sector. The company’s capital structure includes multiple classes of stock, including Series B Non-Voting Convertible Preferred Stock, which can be converted into common stock under specified terms.
Average Trading Volume: 27,898
Technical Sentiment Signal: Sell
Current Market Cap: $1.66M
See more data about GRTX stock on TipRanks’ Stock Analysis page.